{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:31:41Z","timestamp":1789180301482,"version":"build-2803163510"},"reference-count":82,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recombinant erythropoietin (EPO) and iron substitution are a standard of care for treatment of anemias associated with chronic inflammation, including anemia of chronic kidney disease. A black box warning for EPO therapy and concerns about negative side effects related to high-dose iron supplementation as well as the significant proportion of patients becoming EPO resistant over time explains the medical need to define novel strategies to ameliorate anemia of chronic disease (ACD). As hepcidin is central to the iron-restrictive phenotype in ACD, therapeutic approaches targeting hepcidin were recently developed. We herein report the therapeutic effects of a fully human anti-BMP6 antibody (KY1070) either as monotherapy or in combination with Darbepoetin alfa on iron metabolism and anemia resolution in 2 different, well-established, and clinically relevant rodent models of ACD. In addition to counteracting hepcidin-driven iron limitation for erythropoiesis, we found that the combination of KY1070 and recombinant human EPO improved the erythroid response compared with either monotherapy in a qualitative and quantitative manner. Consequently, the combination of KY1070 and Darbepoetin alfa resulted in an EPO-sparing effect. Moreover, we found that suppression of hepcidin via KY1070 modulates ferroportin expression on erythroid precursor cells, thereby lowering potentially toxic-free intracellular iron levels and by accelerating erythroid output as reflected by increased maturation of erythrocyte progenitors. In summary, we conclude that treatment of ACD, as a highly complex disease, becomes more effective by a multifactorial therapeutic approach upon mobilization of endogenous iron deposits and stimulation of erythropoiesis.<\/jats:p>","DOI":"10.1182\/blood.2019004653","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T18:57:16Z","timestamp":1590087436000},"page":"1080-1090","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-1440","authenticated-orcid":false,"given":"Verena","family":"Petzer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"},{"name":"Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-6034","authenticated-orcid":false,"given":"Piotr","family":"Tymoszuk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Asshoff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Kymab Ltd, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Papworth","sequence":"additional","affiliation":[{"name":"Kymab Ltd, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Deantonio","sequence":"additional","affiliation":[{"name":"Kymab Ltd, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Bayliss","sequence":"additional","affiliation":[{"name":"Kymab Ltd, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Stephen","family":"Wake","sequence":"additional","affiliation":[{"name":"Kymab Ltd, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Seifert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"},{"name":"Christian Doppler Laboratory for Iron Metabolism and Anemia Research, Medical University of Innsbruck, Innsbruck, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Brigo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Valente de Souza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"},{"name":"Christian Doppler Laboratory for Iron Metabolism and Anemia Research, Medical University of Innsbruck, Innsbruck, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hilbe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Grubwieser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-927X","authenticated-orcid":false,"given":"Egon","family":"Demetz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Dichtl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3600-4735","authenticated-orcid":false,"given":"Chiara","family":"Volani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"},{"name":"Christian Doppler Laboratory for Iron Metabolism and Anemia Research, Medical University of Innsbruck, Innsbruck, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Pfeifhofer-Obermair","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"von Raffay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2265-1974","authenticated-orcid":false,"given":"Sieghart","family":"Sopper","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Arndt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Regensburg, Regensburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8147-394X","authenticated-orcid":false,"given":"Anja","family":"Bosserhoff","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry, Emil Fischer Center, Friedrich-Alexander University of Erlangen-N\u00fcrnberg, Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9on","family":"Kautz","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Sant\u00e9 Digestive (IRSD), Universit\u00e9 de Toulouse, INSERM U1220, Institut National de la Recherche Agronomique (INRA) U1416, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse (ENVT), Universit\u00e9 Paul Sabatier (UPS), Toulouse, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prunelle","family":"Perrier","sequence":"additional","affiliation":[{"name":"Institut de Recherche en Sant\u00e9 Digestive (IRSD), Universit\u00e9 de Toulouse, INSERM U1220, Institut National de la Recherche Agronomique (INRA) U1416, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse (ENVT), Universit\u00e9 Paul Sabatier (UPS), Toulouse, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Nairz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria;"},{"name":"Internal Medicine 3, Oncology, Oncology, Immunooncology and Rheumatology, University Clinic Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-2158","authenticated-orcid":false,"given":"Guenter","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"},{"name":"Christian Doppler Laboratory for Iron Metabolism and Anemia Research, Medical University of Innsbruck, Innsbruck, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Germaschewski","sequence":"additional","affiliation":[{"name":"Kymab Ltd, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Theurl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology) and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2020082711283823600_B1","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V77.12.2583.2583","article-title":"Erythropoietin receptor characteristics on primary human erythroid cells","volume":"77","author":"Broudy","year":"1991","journal-title":"Blood"},{"issue":"2","key":"2020082711283823600_B2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jcp.1040890212","article-title":"Erythropoietin sensitivity as a differentiation marker in the hemopoietic system: studies of three erythropoietic colony responses in culture","volume":"89","author":"Gregory","year":"1976","journal-title":"J Cell Physiol"},{"issue":"2","key":"2020082711283823600_B3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20131189","article-title":"Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate","volume":"211","author":"Grover","year":"2014","journal-title":"J Exp Med"},{"issue":"Pt 6","key":"2020082711283823600_B4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","article-title":"Regulation of erythropoietin production","volume":"589","author":"Jelkmann","year":"2011","journal-title":"J Physiol"},{"issue":"1","key":"2020082711283823600_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2012.09.005","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations","volume":"7","author":"Van Assche","year":"2013","journal-title":"J Crohn\u2019s Colitis"},{"issue":"8","key":"2020082711283823600_B6","first-page":"11","article-title":"Iron status and hemoglobin level in chronic renal insufficiency","volume":"19","author":"Khan","year":"2008","journal-title":"Med. Forum Mon"},{"issue":"3","key":"2020082711283823600_B7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2016.12.034","article-title":"A red carpet for iron metabolism","volume":"168","author":"Muckenthaler","year":"2017","journal-title":"Cell"},{"issue":"1","key":"2020082711283823600_B8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Iron management in chronic kidney disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int"},{"issue":"4","key":"2020082711283823600_B9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/17474086.2014.941349","article-title":"Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies","volume":"7","author":"Del Vecchio","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"2020082711283823600_B10","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.3390\/nu5082836","article-title":"Iron deprivation in cancer\u2013potential therapeutic implications","volume":"5","author":"Heath","year":"2013","journal-title":"Nutrients"},{"issue":"4","key":"2020082711283823600_B11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrrheum.2012.183","article-title":"Anaemia in inflammatory rheumatic diseases","volume":"9","author":"Weiss","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"3 Suppl 8","key":"2020082711283823600_B12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/sonc.2002.33533","article-title":"Anemia of hematologic malignancies: what are the treatment options?","volume":"29","author":"Ludwig","year":"2002","journal-title":"Semin Oncol"},{"issue":"2","key":"2020082711283823600_B13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin Nephrol"},{"issue":"1","key":"2020082711283823600_B14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020082711283823600_B15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1524-4733.2005.00058.x","article-title":"Economic burden of patients with anemia in selected diseases","volume":"8","author":"Ershler","year":"2005","journal-title":"Value Health"},{"issue":"4","key":"2020082711283823600_B16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/ph11040135","article-title":"Established and emerging concepts to treat imbalances of iron homeostasis in inflammatory diseases","volume":"11","author":"Petzer","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"2020082711283823600_B17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3324\/haematol.2018.195552","article-title":"Association of anemia with health-related quality of life and survival: a large population-based cohort study","volume":"104","author":"Wouters","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"2020082711283823600_B18","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood.V90.6.2244","article-title":"Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells","volume":"90","author":"Taniguchi","year":"1997","journal-title":"Blood"},{"issue":"5704","key":"2020082711283823600_B19","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"issue":"21","key":"2020082711283823600_B20","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1182\/blood-2008-12-195651","article-title":"Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications","volume":"113","author":"Theurl","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2020082711283823600_B21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2020082711283823600_B22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-nutr-071715-050731","article-title":"Regulation of hepcidin by erythropoiesis: the story so far","volume":"36","author":"Pasricha","year":"2016","journal-title":"Annu Rev Nutr"},{"issue":"9","key":"2020082711283823600_B23","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3324\/haematol.2013.099481","article-title":"Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats","volume":"99","author":"Theurl","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"2020082711283823600_B24","doi-asserted-by":"crossref","first-page":"eaaw0109","DOI":"10.1126\/sciadv.aaw0109","article-title":"The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia","volume":"5","author":"Muriuki","year":"2019","journal-title":"Sci. Adv"},{"issue":"19","key":"2020082711283823600_B25","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2018-04-842997","article-title":"Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2020082711283823600_B26","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1063\/1.4946877","article-title":"Development of a reaction cell for in-situ\/operando studies of surface of a catalyst under a reaction condition and during catalysis","volume":"87","author":"Nguyen","year":"2016","journal-title":"Rev Sci Instrum"},{"issue":"6","key":"2020082711283823600_B27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/iub.1629","article-title":"Systemic iron homeostasis and erythropoiesis","volume":"69","author":"Papanikolaou","year":"2017","journal-title":"IUBMB Life"},{"issue":"2","key":"2020082711283823600_B28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.V89.2.680","article-title":"Regulation of cellular iron metabolism by erythropoietin: activation of iron-regulatory protein and upregulation of transferrin receptor expression in erythroid cells","volume":"89","author":"Weiss","year":"1997","journal-title":"Blood"},{"issue":"4","key":"2020082711283823600_B29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/7727","article-title":"Transferrin receptor is necessary for development of erythrocytes and the nervous system","volume":"21","author":"Levy","year":"1999","journal-title":"Nat Genet"},{"issue":"5","key":"2020082711283823600_B30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5414\/CNP60335","article-title":"Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients","volume":"60","author":"DeVita","year":"2003","journal-title":"Clin Nephrol"},{"issue":"9","key":"2020082711283823600_B31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/ki.2012.270","article-title":"Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)","volume":"82","author":"Dr\u00fceke","year":"2012","journal-title":"Kidney Int"},{"issue":"3","key":"2020082711283823600_B32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1681\/ASN.V113530","article-title":"Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients","volume":"11","author":"Besarab","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2020082711283823600_B33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/ph11040094","article-title":"Anemia and iron deficiency in cancer patients: role of iron replacement therapy","volume":"11","author":"Busti","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"2020082711283823600_B34","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1007\/s00520-017-3672-1","article-title":"Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies","volume":"25","author":"Lebrun","year":"2017","journal-title":"Support Care Cancer"},{"issue":"2","key":"2020082711283823600_B35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.20170396","article-title":"Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor","volume":"215","author":"Khalil","year":"2018","journal-title":"J Exp Med"},{"issue":"11","key":"2020082711283823600_B36","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.15252\/embr.201540558","article-title":"The Iron Age of host-microbe interactions","volume":"16","author":"Soares","year":"2015","journal-title":"EMBO Rep"},{"issue":"4","key":"2020082711283823600_B37","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"2020082711283823600_B38","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1053\/ajkd.2001.22433","article-title":"Serum ferritin is a marker of morbidity and mortality in hemodialysis patients","volume":"37","author":"Kalantar-Zadeh","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2020082711283823600_B39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1039\/C7MT00282C","article-title":"Iron reduction response and demographic differences between diabetics and non-diabetics with cardiovascular disease entered into a controlled clinical trial","volume":"10","author":"Zacharski","year":"2018","journal-title":"Metallomics"},{"issue":"12","key":"2020082711283823600_B40","doi-asserted-by":"crossref","first-page":"118535","DOI":"10.1016\/j.bbamcr.2019.118535","article-title":"Iron homeostasis and oxidative stress: An intimate relationship","volume":"1866","author":"Galaris","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"20","key":"2020082711283823600_B41","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"issue":"20","key":"2020082711283823600_B42","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2020082711283823600_B43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.critrevonc.2008.03.006","article-title":"The erythropoietin receptor in normal and cancer tissues","volume":"67","author":"Jelkmann","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"2020082711283823600_B44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fphar.2016.00160","article-title":"Pharmacological targeting of the hepcidin\/ferroportin axis","volume":"7","author":"Sebastiani","year":"2016","journal-title":"Front Pharmacol"},{"issue":"4","key":"2020082711283823600_B45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2016-07-729822","article-title":"Angiocrine Bmp2 signaling in murine liver controls normal iron homeostasis","volume":"129","author":"Koch","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020082711283823600_B46","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.320","article-title":"Lack of the bone morphogenetic protein BMP6 induces massive iron overload","volume":"41","author":"Meynard","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"2020082711283823600_B47","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.335","article-title":"BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism","volume":"41","author":"Andriopoulos","year":"2009","journal-title":"Nat Genet"},{"issue":"11","key":"2020082711283823600_B48","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajh.24888","article-title":"Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6","volume":"92","author":"Canali","year":"2017","journal-title":"Am J Hematol"},{"issue":"18","key":"2020082711283823600_B49","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2011-03-345066","article-title":"Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats","volume":"118","author":"Theurl","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2020082711283823600_B50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ibd.21675","article-title":"The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease","volume":"18","author":"Wang","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"17","key":"2020082711283823600_B51","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2018-03-841197","article-title":"Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6\/Hjv\/Smad signaling","volume":"132","author":"Fillebeen","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2020082711283823600_B52","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood-2015-11-681494","article-title":"Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice","volume":"127","author":"Nai","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2020082711283823600_B53","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2020082711283823600_B54","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nbt.2825","article-title":"Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery","volume":"32","author":"Lee","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"13","key":"2020082711283823600_B55","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020082711283823600_B56","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jnutbio.2011.10.013","article-title":"High-fat diet causes iron deficiency via hepcidin-independent reduction of duodenal iron absorption","volume":"23","author":"Sonnweber","year":"2012","journal-title":"J Nutr Biochem"},{"issue":"5","key":"2020082711283823600_B57","doi-asserted-by":"crossref","first-page":"F877","DOI":"10.1152\/ajprenal.00089.2016","article-title":"Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease","volume":"311","author":"Akchurin","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"2020082711283823600_B58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood-2016-12-759423","article-title":"Smad1\/5 is required for erythropoietin-mediated suppression of hepcidin in mice","volume":"130","author":"Wang","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2020082711283823600_B59","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism [published correction appears in Nat Genet. 2020;52(4):463]","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"issue":"41","key":"2020082711283823600_B60","doi-asserted-by":"crossref","first-page":"24209","DOI":"10.1074\/jbc.270.41.24209","article-title":"Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II)","volume":"270","author":"Breuer","year":"1995","journal-title":"J Biol Chem"},{"issue":"3","key":"2020082711283823600_B61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/ph11030082","article-title":"Intravenous irons: from basic science to clinical practice","volume":"11","author":"Bhandari","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"2020082711283823600_B62","doi-asserted-by":"crossref","first-page":"e0158599","DOI":"10.1371\/journal.pone.0158599","article-title":"Intravenous iron carboxymaltose as a potential therapeutic in anemia of inflammation","volume":"11","author":"Lofruthe","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"2020082711283823600_B63","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.yexcr.2017.05.004","article-title":"Therapeutic targeting of the HIF oxygen-sensing pathway: lessons learned from clinical studies","volume":"356","author":"Haase","year":"2017","journal-title":"Exp Cell Res"},{"issue":"11","key":"2020082711283823600_B64","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3324\/haematol.2013.084624","article-title":"Manipulation of the hepcidin pathway for therapeutic purposes","volume":"98","author":"Fung","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"2020082711283823600_B65","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1182\/blood-2010-10-313064","article-title":"Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation","volume":"117","author":"Steinbicker","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2020082711283823600_B66","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bcp.13877","article-title":"Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease","volume":"85","author":"Sheetz","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2020082711283823600_B67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-nutr-082117-051732","article-title":"Iron and cancer","volume":"38","author":"Torti","year":"2018","journal-title":"Annu Rev Nutr"},{"issue":"17","key":"2020082711283823600_B68","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020082711283823600_B69","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/SHK.0000000000000886","article-title":"In a mouse model of sepsis, hepcidin ablation ameliorates anemia more effectively than iron and erythropoietin treatment","volume":"48","author":"Khorramian","year":"2017","journal-title":"Shock"},{"issue":"1","key":"2020082711283823600_B70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2018-07-815928","article-title":"Iron metabolism under conditions of ineffective erythropoiesis in \u03b2-thalassemia","volume":"133","author":"Rivella","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2020082711283823600_B71","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2016-09-742387","article-title":"Decreasing TfR1 expression reverses anemia and hepcidin suppression in \u03b2-thalassemic mice","volume":"129","author":"Li","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020082711283823600_B72","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1172\/JCI41717","article-title":"Hepcidin as a therapeutic tool to limit iron overload and improve anemia in \u03b2-thalassemic mice","volume":"120","author":"Gardenghi","year":"2010","journal-title":"J Clin Invest"},{"issue":"8","key":"2020082711283823600_B73","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2016.1182494","article-title":"An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease","volume":"15","author":"Del Vecchio","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2020082711283823600_B74","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MNH.0b013e32833cf1d6","article-title":"What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?","volume":"19","author":"Singh","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"2020082711283823600_B75","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrneph.2013.21","article-title":"Anaemia management and mortality risk in chronic kidney disease","volume":"9","author":"H\u00f6rl","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"2020082711283823600_B76","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2020082711283823600_B77","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"2020082711283823600_B78","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1111\/hdi.12567","article-title":"HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism","volume":"21","author":"Haase","year":"2017","journal-title":"Hemodial Int"},{"issue":"8","key":"2020082711283823600_B79","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1086\/382878","article-title":"Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy","volume":"38","author":"Teehan","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2020082711283823600_B80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000187285","article-title":"Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey","volume":"64","author":"Kessler","year":"1993","journal-title":"Nephron"},{"issue":"5","key":"2020082711283823600_B81","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1681\/ASN.V95869","article-title":"EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients","volume":"9","author":"Hoen","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2020082711283823600_B82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/9\/1080\/1755919\/bloodbld2019004653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/9\/1080\/1755919\/bloodbld2019004653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T10:45:19Z","timestamp":1666608319000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/9\/1080\/456038\/A-fully-human-antiBMP6-antibody-reduces-the-need"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019004653","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]}}}